EPHA2 and neoplasm: In the EMT6 breast tumor model, the deployment of EphA2-targeted liposomal paclitaxel, termed “EphA2-il-dtxp”, in conjunction with the PD-L1 blockade, elicited a significant tumor response in vivo.